Co-Diagnostics (NASDAQ:CODX – Get Free Report) will be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect Co-Diagnostics to post earnings of ($0.33) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.09. The business had revenue of $2.66 million for the quarter, compared to the consensus estimate of $0.40 million. Co-Diagnostics had a negative net margin of 411.18% and a negative return on equity of 44.69%. On average, analysts expect Co-Diagnostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Co-Diagnostics Stock Performance
CODX stock opened at $1.22 on Thursday. The company has a 50 day moving average price of $1.30 and a two-hundred day moving average price of $1.25. The stock has a market capitalization of $38.93 million, a P/E ratio of -0.92 and a beta of -0.87. Co-Diagnostics has a one year low of $1.00 and a one year high of $2.23.
Analysts Set New Price Targets
View Our Latest Stock Analysis on CODX
Co-Diagnostics Company Profile
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
Featured Articles
- Five stocks we like better than Co-Diagnostics
- Compound Interest and Why It Matters When Investing
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- 3 Stocks to Consider Buying in October
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- What Do S&P 500 Stocks Tell Investors About the Market?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.